Synthetic Biologics (SYN) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
August 11, 2022 8:00 AM EDT-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform-
-Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024-
-Conference call and webcast to be held today at 8:30 a.m. ET-
ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Synthetic... More
